Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Roger Douglas Weiss, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21DA041682 (CHAN, KEVIN E) Mar 15, 2017 - Feb 28, 2019
    NIH
    Opioid Use and Abuse in the Dialysis Population
    Role: Co-Principal Investigator
  2. K24DA022288 (WEISS, ROGER D.) Apr 1, 2007 - Mar 1, 2019
    NIH
    Mentoring in drug abuse and dual diagnosis research
    Role: Principal Investigator
  3. UG1DA015831 (D'ONOFRIO, GAIL) Sep 30, 2002 - Feb 28, 2025
    NIH
    The National Drug Abuse Clinical Trials Network: New England Consortium Node
    Role: Co-Principal Investigator
  4. U10DA015831 (WEISS, ROGER D.) Sep 30, 2002 - Aug 31, 2015
    NIH
    The National Drug Abuse Treatment Clinical Trials Network (U10)
    Role: Co-Principal Investigator
  5. R01DA015968 (WEISS, ROGER D.) Sep 30, 2002 - Jan 31, 2009
    NIH
    Modifying Group Therapy for Bipolar Abusers
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW, Kampman KM, Pravetoni M, Preston KL, Vandrey R, Bergeria CL, Bogenschutz MP, Brown RT, Dunn KE, Dworkin RH, Finan PH, Hendricks PS, Houtsmuller EJ, Kosten TR, Lee DC, Levin FR, McRae-Clark A, Raison CL, Rasmussen K, Turk DC, Weiss RD, Strain EC. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023 01 01; 80(1):84-92. PMID: 36449315.
    Citations:    Fields:    Translation:Humans
  2. Pan Y, Feaster DJ, Odom G, Brandt L, Hu MC, Weiss RD, Rotrosen J, Saxon AJ, Luo SX, Balise RR. Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. Drug Alcohol Depend Rep. 2022 Dec; 5. PMID: 36644227; PMCID: PMC9838120.
    Citations:    
  3. Schuman-Olivier Z, Fatkin T, Creedon TB, Samawi F, Moore SK, Okst K, Fredericksen AK, Oxnard AS, Roll D, Smith L, Cook BL, Weiss RD. Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study. Am J Addict. 2022 Dec 05. PMID: 36470641.
    Citations:    Fields:    
  4. McCarthy JM, Wood AJ, Shinners MG, Heinrich H, Weiss RD, Mueser KT, Meyers RJ, Carol EE, Hudson JI, Öngür D. Pilot development and feasibility of telehealth Community Reinforcement and Family Training (CRAFT) for early psychosis and substance use. Psychiatry Res. 2022 11; 317:114804. PMID: 36030701.
    Citations:    Fields:    Translation:Humans
  5. Kleinman RA, Nielsen S, Weiss RD. Is daily supervised buprenorphine-naloxone dosing necessary? BMJ. 2022 08 16; 378:e071467. PMID: 35973725.
    Citations: 2     Fields:    Translation:Humans
  6. Provost SE, Griffin ML, Hilton BT, McHugh RK, Taghian NR, Trinh CD, Weiss RD. Correlates of optimism among patients in substance use disorder inpatient treatment. Am J Addict. 2022 11; 31(6):494-501. PMID: 35975406.
    Citations:    Fields:    Translation:Humans
  7. Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study. Integr Med Rep. 2022 Aug 01; 1(1):157-163. PMID: 36105269.
    Citations:    
  8. Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022 09; 117(9):2438-2447. PMID: 35293064; PMCID: PMC9543602.
    Citations:    Fields:    
  9. Kleinman RA, Weiss RD. Benzodiazepine-Involved Overdose Deaths in the USA: 2000-2019. J Gen Intern Med. 2022 06; 37(8):2103-2109. PMID: 35415793; PMCID: PMC9198172.
    Citations:    Fields:    Translation:Humans
  10. Weiner SG, Hendricks MA, El Ibrahimi S, Ritter GA, Hallvik SE, Hildebran C, Weiss RD, Boyer EW, Flores DP, Nelson LS, Kreiner PW, Fischer MA. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone. PLoS One. 2022; 17(4):e0266561. PMID: 35381052; PMCID: PMC8982846.
    Citations:    Fields:    Translation:Humans
  11. Connery HS, Weiss RD, Griffin ML, Trinh CD, Kim J, Rockett IRH, McHugh RK. Suicidal motivations among opioid overdose survivors: Replication and extension. Drug Alcohol Depend. 2022 06 01; 235:109437. PMID: 35427980; PMCID: PMC9106902.
    Citations:    Fields:    Translation:Humans
  12. McHugh RK, Chase A, Trinh CD, Weiss RD. Are Pain and Negative Affect Coping Distinct Motives for Opioid Misuse? Subst Use Misuse. 2022; 57(6):848-852. PMID: 35258408; PMCID: PMC9069863.
    Citations:    Fields:    Translation:Humans
  13. Copersino ML, Slayter E, McHugh RK, Shedlack KJ, Lukas SE, Weiss RD. Clinical utility of a hybrid secondary and relapse prevention program in adults with mild intellectual disability or borderline intellectual functioning in community residential and day habilitation settings. Disabil Health J. 2022 06; 15(2S):101293. PMID: 35337784.
    Citations:    Fields:    Translation:HumansPHPublic Health
  14. Weiner SG, El Ibrahimi S, Hendricks MA, Hallvik SE, Hildebran C, Fischer MA, Weiss RD, Boyer EW, Kreiner PW, Wright DA, Flores DP, Ritter GA. Factors Associated With Opioid Overdose After an Initial Opioid Prescription. JAMA Netw Open. 2022 01 04; 5(1):e2145691. PMID: 35089351; PMCID: PMC8800077.
    Citations: 1     Fields:    Translation:Humans
  15. McHugh RK, Hilton BT, Chase AM, Griffin ML, Weiss RD. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine? Drug Alcohol Depend. 2021 11 01; 228:109084. PMID: 34607194; PMCID: PMC8595708.
    Citations:    Fields:    Translation:Humans
  16. Sugarman DE, Busch AB, McHugh RK, Bogunovic OJ, Trinh CD, Weiss RD, Greenfield SF. Patients' perceptions of telehealth services for outpatient treatment of substance use disorders during the COVID-19 pandemic. Am J Addict. 2021 09; 30(5):445-452. PMID: 34405475.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  17. Strain EC, Kampman KM, Weiss RD. Moving Beyond Medications That Act at the µ Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry. 2021 07 01; 78(7):701-702. PMID: 33851964.
    Citations:    Fields:    Translation:Humans
  18. Hilton BT, Yusufov M, Rosellini AJ, Taghian NR, Weiss RD, Griffin ML, McHugh RK. Psychometric properties of the Anxiety Sensitivity Index-3 in adults with substance use disorders. J Subst Abuse Treat. 2022 01; 132:108507. PMID: 34214925.
    Citations:    Fields:    Translation:Humans